These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23741880)

  • 1. BCG immunotherapy as an adjunct to chemotherapy in BL-lL patients--its effect on clinical regression, reaction severity, nerve function, lepromin conversion, bacterial/antigen clearance and 'persister' M. leprae.
    Shetty VP; Mistry NF; Wakade AV; Ghate SD; Capadia GD; Pai VV
    Lepr Rev; 2013 Mar; 84(1):23-40. PubMed ID: 23741880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
    Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
    Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
    Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of far-advanced lepromatous leprosy patients with low-dose convit vaccine along with multidrug therapy (Calcutta trial).
    Majumder V; Mukerjee A; Hajra SK; Saha B; Saha K
    Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):26-36. PubMed ID: 8627110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):259-69. PubMed ID: 10575405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
    Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):250-8. PubMed ID: 10575404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy.
    Kamal R; Natrajan M; Katoch K; Arora M
    Indian J Lepr; 2012; 84(4):287-306. PubMed ID: 23720894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
    Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
    Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization potential and reactogenicity of BCG with and without various doses of killed Mycobacterium leprae.
    Gupte MD; Anantharaman DS; De Britto RL; Vallishayee RS; Nagaraju B; Kannan S; Sengupta U
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):340-52. PubMed ID: 1474275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of corticosteroid usage on the bacterial killing, clearance and nerve damage in leprosy: a prospective cohort study: part 1--study design and baseline findings of 400 untreated multibacillary patients.
    Khambati FA; Shetty VP; Ghate SD; Capadia GD; Pai VV; Ganapati R
    Lepr Rev; 2008 Jun; 79(2):134-53. PubMed ID: 18711936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients.
    Shinde SR; Chiplunkar SV; Butlin R; Samson PD; Deo MG; Gangal SG
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):51-8. PubMed ID: 8326181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional lymphadenitis following antileprosy vaccine BCG with killed Mycobacterium leprae.
    De Britto RL; Ramanathan VD; Gupte MD
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):12-9. PubMed ID: 9207749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT).
    Rada E; Ulrich M; Aranzazu N; Rodriguez V; Centeno M; Gonzalez I; Santaella C; Rodriguez M; Convit J
    Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):320-7. PubMed ID: 9401484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons form Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma.
    Chaudhuri S; Hajra SK; Mukherjee A; Saha B; Mazumder B; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):182-9. PubMed ID: 9728450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG.
    Convit J; Aranzazu N; Pinardi M; Ulrich M
    Clin Exp Immunol; 1979 May; 36(2):214-20. PubMed ID: 383331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of skin reactions in leprosy patients to M. leprae-lepromin and to ICRC-in, an antigen from cultivable acid-fast bacilli from M. leprae isolated from lepromatous nodules.
    Bapat CV; Modak MS; DeSouza NG; Chulawalla RG
    Lepr India; 1977 Oct; 49(4):472-84. PubMed ID: 342823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.